Key Notes
- Veradermics shares closed at $127.23 on October 20, up 4.05% a day after positive Phase 3 data for investigational VDPHL01.
- The 536-participant male trial met its primary and secondary endpoints, with both treatment groups outperforming placebo on hair counts and patient-reported benefit.
- Longer-term male results and a female trial readout remain ahead, while the company has not received FDA approval for the treatment.
Veradermics Inc. (NYSE: MANE) shares gained 4.05% to close at $127.23 on October 20, a day after the company reported positive Phase 3 results for its experimental oral treatment for male pattern hair loss.
The company said VDPHL01 met every primary and secondary endpoint in Study 304, a randomized, double-blind, placebo-controlled trial involving 536 men. The results strengthen the development case for its extended-release minoxidil tablet, although the drug remains investigational and has not received FDA approval.
Nasdaq’s trading data show Tuesday’s regular-session gain was $4.95 a share from Monday’s $122.28 close. That is the closing return, separate from subsequent after-hours trading.
Two Measures Showed Benefit at Six Months
Veradermics’ October 19 announcement reported average increases of 28.6 hairs per square centimeter with once-daily treatment and 36.4 with twice-daily treatment, compared with 6.6 for placebo at six months.
The differences relative to placebo were therefore 22.0 and 29.8 hairs per square centimeter. These figures measure changes in a defined target area; they are not percentages of hair restored across the entire scalp.
On the other co-primary endpoint, 55.7% and 68.7% of participants in the respective treatment groups reported improved or much improved hair coverage, versus 15% with placebo. Both treatment regimens met the co-primary endpoints with p-values below 0.0001.
The study record identifies both digital target-area hair counts and participants’ assessments of treatment benefit as primary outcomes at month six. Using both measures tests whether an objective change is accompanied by improvement participants notice.
Safety Findings Still Need Longer Follow-Up
The company reported no treatment-related serious adverse events and no cardiac adverse events of special interest in Study 304. Those findings describe what was observed during the study period and do not establish that the treatment is free of risk.
Reported side effects included peripheral edema in 2.8% of once-daily participants and 4.5% of twice-daily participants, compared with 0.6% receiving placebo. Hypertrichosis, or unwanted hair growth, occurred in 2.2% and 9.0% of the treatment groups, respectively, versus none in the placebo group.
For investors, tolerability matters alongside hair growth because a chronic treatment must be acceptable for continued use. The six-month comparison provides evidence on that question, while longer follow-up will add information about continued treatment.
The Development Program Has More Readouts Ahead
Study 304 follows positive findings from the earlier male Study 302. Veradermics expects 12-month results from that earlier study later in 2026, extending the period covered by its reported safety data.
The broader program also includes Study 306 in women. In its August business update, the company said enrollment was complete at 556 participants and forecast topline results in the first half of 2027.
The newly announced male trial cannot establish the outcome of the female study. Separate results will determine how that part of the development program progresses.
VDPHL01 uses an extended-release formulation of minoxidil. The commercial proposition rests on the performance and regulatory acceptance of that specific product, rather than simply on familiarity with the underlying ingredient.
Cash Runway Gives MANE a Financial Buffer
Veradermics reported $819.9 million in cash, cash equivalents and marketable securities at June 30. Management said that balance was expected to fund its operating plan into 2030, including clinical readouts and a potential commercial launch if approval is obtained.
That is a dated balance-sheet figure and a management runway estimate, not a statement of cash on hand today. Development, staffing and launch-preparation spending continue between reporting periods.
The company recorded a $23.5 million second-quarter net loss. Research and development expenses were $18.6 million, while general and administrative expenses reached $10.9 million as it expanded staffing and commercial-readiness work.
The financial position gives investors a separate dimension to assess alongside clinical progress. Funding capacity can support the path toward a launch, but it does not determine whether regulators will approve the medicine or how much revenue it could eventually earn.
MANE Still Faces Regulatory and Commercial Tests
Clinical announcements can produce large biotechnology share moves, but the underlying catalysts differ. We previously reported Silence Therapeutics’ surge after an agreed cash acquisition. Veradermics’ investment case remains tied to development, approval and eventual commercialization.
The latest trial adds evidence for that case. It does not establish an approved prescribing label, launch date, price or level of patient adoption.
For MANE investors, the next concrete checkpoints are longer-term male data, the female trial readout and further regulatory progress. Tuesday’s share-price gain reflects the market’s response to an advancing program; the business still has to convert clinical results into an authorized, commercially viable product.
